List of Excipients in Branded Drug TASIMELTEON

Generic Drugs Containing TASIMELTEON

Company	Ingredient	NDC	Excipient
Teva Pharmaceuticals Inc	tasimelteon	0480-4490	ANHYDROUS LACTOSE
Teva Pharmaceuticals Inc	tasimelteon	0480-4490	CELLULOSE, MICROCRYSTALLINE
Teva Pharmaceuticals Inc	tasimelteon	0480-4490	CROSCARMELLOSE SODIUM
Teva Pharmaceuticals Inc	tasimelteon	0480-4490	FD&C BLUE NO. 1
Teva Pharmaceuticals Inc	tasimelteon	0480-4490	FD&C RED NO. 40
Teva Pharmaceuticals Inc	tasimelteon	0480-4490	FERROSOFERRIC OXIDE

What are the Most Frequently-Used Excipients in TASIMELTEON?

# Of NDCs	Excipient
1	ANHYDROUS LACTOSE
2	CELLULOSE, MICROCRYSTALLINE
3	CROSCARMELLOSE SODIUM
3	FD&C BLUE NO. 1
1	FD&C RED NO. 3
2	FD&C RED NO. 40

Tasimelteon Excipient Strategy and Commercial Opportunities

Last updated: August 6, 2026

Tasimelteon has two approved dosage-form platforms: a 20 mg capsule and an oral suspension, Hetlioz LQ. The primary commercial opportunity is not a new active ingredient but better delivery for pediatric patients, patients with swallowing difficulty, long-term caregivers, and markets where suspension logistics are costly. Excipients can improve palatability, dose flexibility, physical stability, manufacturability, and global regulatory acceptance.

Vanda Pharmaceuticals commercializes Hetlioz in the United States. The FDA-approved capsule is indicated for Non-24-Hour Sleep-Wake Disorder in adults and for nighttime sleep disturbances associated with Smith-Magenis Syndrome. Hetlioz LQ provides a liquid option for eligible pediatric and adult patients with Smith-Magenis Syndrome.[1]

What excipients are used in approved tasimelteon products?

The approved capsule uses conventional solid oral excipients. The formulation includes a diluent, disintegrant, lubricant, and capsule-shell colorants. Hetlioz LQ uses a liquid vehicle with buffering, preservation, sweetening, and flavoring functions.[1,2]

Product	Strength and form	Primary excipient functions	Commercial relevance
Hetlioz	20 mg capsule	Dilution, powder flow, disintegration, lubrication, capsule identification	Low-cost, scalable solid dosage form
Hetlioz LQ	4 mg/mL oral suspension	Vehicle, pH control, preservation, sweetness, flavor, redispersibility	Pediatric dosing and swallowing support
Potential multiparticulate product	Dose-flexible granules or sachet	Taste masking, dose subdivision, rapid dispersion	Pediatric and adherence-focused opportunity
Potential orally disintegrating product	Fast-dissolving tablet or granule	Rapid wetting, taste masking, low-volume administration	Patients unable to swallow capsules

The capsule formulation is technically conventional. Its main advantages are manufacturing simplicity, limited excipient burden, and established regulatory familiarity. The suspension has greater formulation complexity because tasimelteon must remain uniformly distributed during storage and dosing while maintaining acceptable taste and microbiological quality.

What formulation challenges affect tasimelteon product development?

Tasimelteon formulation development is driven by dose accuracy, palatability, physical stability, and patient population rather than by high-dose loading. A 20 mg capsule is relatively easy to manufacture, but a pediatric liquid must deliver a reproducible dose at a small administration volume.

Taste masking

Taste masking is the largest commercial formulation opportunity. Pediatric and neurologically impaired patients may reject a bitter or solvent-like formulation. A successful product would combine:

• A pharmaceutical-grade flavor system
• High-intensity sweeteners with acceptable aftertaste
• Polymer coating or lipid-based taste masking
• Rapid dispersion after swallowing
• Low sedimentation and easy redispersion

Taste masking can be implemented in coated granules, multiparticulates, orally disintegrating tablets, mini-tablets, or sprinkle formulations. A coated-particle approach could separate tasimelteon from the mouth while preserving rapid release in the gastrointestinal tract.

Dose flexibility

A liquid supports weight-based and age-specific dosing, but it creates risks involving measurement error, storage, shipping, and caregiver handling. A dry granule product reconstituted at the point of use could reduce shipping weight and improve shelf life.

Potential dose-flexible formats include:

• Single-dose sachets
• Unit-dose oral powders
• Sprinkle capsules
• Mini-tablets
• Concentrated oral solutions or suspensions
• Premeasured oral syringes

A 4 mg/mL suspension requires 5 mL to deliver 20 mg. A more concentrated product could reduce administration volume, but increased concentration may worsen sedimentation, viscosity, taste, or dose uniformity.

Physical stability

A suspension must control particle size, settling rate, caking, redispersibility, viscosity, and dose uniformity. Candidate excipient classes include suspending polymers, wetting agents, structured vehicles, and density-modifying components.

The formulation target is not maximum viscosity. Excessive viscosity can impair syringe withdrawal and increase dosing variability. The preferred system usually has controlled settling with rapid redispersion after gentle shaking.

Chemical stability

Liquid products face hydrolysis, oxidation, photodegradation, and preservative loss. Buffer selection must balance chemical stability against taste and tolerability. The formulation should be assessed across:

• Refrigerated and room-temperature storage
• In-use storage after opening
• Repeated bottle access
• Light exposure
• Headspace oxygen
• Container-closure interactions
• Compatibility with oral syringes

A dry suspension or powder-for-reconstitution platform may provide a stronger stability profile than a ready-to-use liquid, particularly in hot and humid markets.

What excipient platforms have the strongest commercial potential?

The most attractive opportunity is a pediatric, taste-masked, dose-flexible product that reduces the handling disadvantages of the current liquid suspension.

Excipient platform	Target benefit	Development risk	Commercial value
Coated multiparticulates	Taste masking and sprinkle administration	Medium	High
Dry powder for reconstitution	Longer shelf life and lower shipping burden	Medium	High
High-solids suspension vehicle	Lower dose volume	Medium-high	Medium-high
Orally disintegrating tablet excipients	No water required	Medium	Medium
Lipid-based formulation	Solubility and taste control	High	Selective
Standard capsule excipient optimization	Cost and process improvement	Low	Low-medium
Unit-dose sachets	Adherence and dosing accuracy	Medium	Medium-high

A coated multiparticulate product could be commercially differentiated without changing the active dose. It could allow administration by sprinkling onto soft food, provided the coating remains intact during handling and releases appropriately after ingestion.

A dry powder for reconstitution could address several weaknesses of liquid products. The commercial model would need to account for pharmacy reconstitution, caregiver instructions, beyond-use dating, and the availability of a suitable dosing device.

What formulation patents could protect a new tasimelteon product?

Excipient selection alone generally provides weak exclusivity. A formulation patent is stronger when it claims a specific technical combination linked to measurable performance.

Potential patentable elements include:

• Tasimelteon particle size and morphology
• Polymer-coated tasimelteon particles
• Defined coating weight gain and release profile
• A specific suspension vehicle and pH range
• Preservative concentration with demonstrated in-use stability
• Redispersibility after defined storage conditions
• A concentrated formulation with a specified viscosity range
• Unit-dose sachet composition
• Multiparticulate administration with soft food
• A dry powder that forms a stable suspension after reconstitution
• A formulation with reduced food-effect variability
• A container-closure system that preserves dose uniformity

A claim directed only to a list of common excipients may face enablement, written-description, obviousness, and lack-of-unexpected-results challenges. A stronger filing would connect the excipient combination to a defined problem, such as improved taste masking without delayed release or improved suspension uniformity without excessive viscosity.

How should excipient IP be structured?

A practical patent program would use several claim layers:

1. Composition claims covering the tasimelteon-excipient combination.
2. Particle or coating claims covering the physical architecture.
3. Performance claims covering dissolution, sedimentation, redispersibility, or taste masking.
4. Manufacturing claims covering granulation, coating, milling, or reconstitution.
5. Packaging claims covering unit-dose delivery or dosing-device compatibility.
6. Method-of-use claims directed to administration in pediatric or swallowing-impaired patients.

Trade-secret protection remains relevant for flavor systems, coating process parameters, granulation conditions, and scale-up controls. Trade secrets do not prevent independent development of a similar formulation, so they should complement, not replace, composition and process patents.

What is the FDA regulatory status of tasimelteon formulations?

The FDA approved Hetlioz in 2014 for Non-24-Hour Sleep-Wake Disorder in totally blind adults. The FDA later approved the Smith-Magenis Syndrome indication and Hetlioz LQ oral suspension for pediatric use.[1,3]

A new tasimelteon formulation would normally require an FDA pathway determined by the relationship to the reference product and the proposed labeling. The principal routes are:

• An ANDA, if the product can meet applicable pharmaceutical equivalence and bioequivalence requirements.
• A 505(b)(2) application, if the formulation differs materially or requires reliance on FDA findings for tasimelteon.
• A supplemental application for the existing sponsor, if the product is developed by the NDA holder.

A suspension, orally disintegrating product, or multiparticulate formulation may create bioequivalence questions involving food effect, particle size, release, and dose administration. The applicant would need to establish pharmaceutical quality, stability, dose uniformity, dissolution, microbiological control, and clinical performance where required.[4]

What is the Orange Book and generic-entry position for Hetlioz?

Hetlioz is an FDA-approved prescription product listed in the Orange Book under tasimelteon. Orange Book analysis must distinguish between active-ingredient patents, method-of-use patents, formulation patents, and regulatory exclusivity.[5]

For commercial planning, the key questions are:

• Which patents are listed for the capsule?
• Are separate patents listed for Hetlioz LQ?
• What are the expiration dates, pediatric extensions, and terminal disclaimers?
• Does an ANDA applicant need a Paragraph IV certification?
• Are any listed patents limited to methods of use rather than the product itself?
• Do formulation differences create a 505(b)(2) opportunity rather than a conventional ANDA?

A generic capsule may face a different barrier profile from a liquid suspension. The capsule is likely to be the simpler target because it uses a conventional oral solid dosage form. The suspension may have greater manufacturing and bioequivalence complexity, which can delay entry even where patent protection is limited.

FDA regulatory exclusivity is separate from patent protection. Pediatric exclusivity, orphan-drug considerations, and approved-use limitations can affect timing, but none should be treated as equivalent to a formulation patent. The Orange Book and FDA product-specific guidance should be reviewed as part of any launch or licensing decision.[4,5]

When does tasimelteon lose exclusivity?

The practical loss-of-exclusivity date depends on the relevant Orange Book patents, pediatric extensions, regulatory exclusivity, and any litigation settlement. Patent expiration should be calculated from the actual listed patent term, including patent-term adjustment, patent-term extension, terminal disclaimer, and pediatric extension.

The commercial sequence usually has four stages:

Stage	Commercial effect
Patent and regulatory protection active	Limited direct generic competition
Paragraph IV filing or patent challenge	Litigation and potential settlement risk
Patent expiry or licensed entry date	ANDA launch becomes possible
Multiple generic entrants	Rapid price and market-share pressure

A generic entrant may launch at risk before final patent resolution, but that decision depends on litigation posture, damages exposure, injunction risk, and settlement terms. A formulation with separate, later-expiring IP could delay competition for a specific dosage form but would not necessarily block all capsule or suspension entry.

Which companies are most likely to challenge tasimelteon?

The most credible challengers are established generic manufacturers with:

• Existing CNS and sleep-disorder portfolios
• Oral solid dosage manufacturing capacity
• Experience with Paragraph IV litigation
• Suspension or pediatric liquid capability
• Commercial infrastructure for specialty pharmacy products

Large generic companies may prioritize the capsule because it offers simpler manufacturing and broader pharmacy distribution. A smaller specialty manufacturer may target the liquid or a differentiated pediatric formulation where competition is less direct.

The competitive risk is asymmetric. A capsule challenger can compete on price, while a differentiated pediatric formulation can compete on administration, adherence, caregiver convenience, and access. The latter may preserve premium pricing if the product demonstrates clinically meaningful usability advantages.

How strong is the commercial opportunity for a new excipient-based product?

The strongest opportunity is a product that solves a recognized administration problem and has a defensible regulatory position. A reformulation that only changes fillers or flavor is unlikely to support durable premium pricing.

High-value opportunities

A taste-masked multiparticulate product has the clearest strategic rationale. It could expand administration options for children, patients with dysphagia, and caregivers who struggle with liquid dosing.

A dry powder for reconstitution has strong logistics value. It may reduce the weight and volume of shipments, improve storage stability, and simplify international distribution.

A unit-dose liquid or powder may improve adherence and reduce dosing errors in institutional, residential, and home-care settings.

Lower-value opportunities

A new capsule with substantially similar excipients is unlikely to create meaningful differentiation unless it improves dissolution, food-effect performance, manufacturing cost, or supply reliability.

A high-concentration liquid may have limited value if it increases taste, viscosity, or sedimentation problems. Reduced volume alone does not justify a new product without demonstrated caregiver benefit.

How does tasimelteon compare with competing sleep medicines?

Tasimelteon has a narrower commercial position than broad insomnia products because its core value is linked to circadian rhythm regulation and specific sleep-wake disorders. The excipient strategy should therefore focus on patient access and administration rather than mass-market insomnia positioning.

Product category	Typical formulation opportunity	Tasimelteon implication
Melatonin products	Gummies, liquids, tablets	Strong consumer competition but variable regulatory status
Ramelteon	Conventional tablets	Competes in melatonin-receptor pharmacology
Sedative-hypnotics	Tablets and capsules	Different safety and mechanism profile
Tasimelteon	Capsule and oral suspension	Opportunity for pediatric and adherence-focused delivery

Tasimelteon’s branded formulation opportunity is strongest where the diagnosis, prescribing pathway, and caregiver need support premium reimbursement. A reformulation should be designed around Smith-Magenis Syndrome and circadian-rhythm treatment rather than generic insomnia demand.

What manufacturing and geographic barriers affect excipient commercialization?

The United States is the principal market for the current commercial franchise, but geographic expansion creates distinct excipient requirements. A ready-to-use suspension may face higher transport, temperature, and shelf-life costs outside North America. A dry powder or sachet could improve distribution economics in Europe, Asia, Latin America, and other markets with variable cold-chain and pharmacy infrastructure.

Key manufacturing barriers include:

• Consistent tasimelteon particle size
• Uniform coating at commercial scale
• Control of suspension sedimentation
• Preservative effectiveness
• Flavor reproducibility
• Container-closure compatibility
• Oral-syringe dosing accuracy
• Cleaning validation for low-dose active handling
• Supplier qualification for critical polymers and flavors

Critical excipients should have at least two qualified suppliers where possible. Colorants, flavors, preservatives, and specialty coating polymers can create supply interruptions or country-specific regulatory restrictions.

Geographic filings should cover composition, manufacturing, reconstitution, dosing devices, and administration with food. U.S. patents alone will not protect a global reformulation. Patent term, patentability standards, supplementary protection rights, and regulatory data protection vary by jurisdiction.

What licensing deals could support a tasimelteon reformulation?

A licensing transaction could involve Vanda, a generic manufacturer, a specialty pediatric company, or an excipient technology provider. The most valuable assets would include:

• A validated taste-masking platform
• A stable dry suspension
• A low-volume pediatric liquid
• A ready-to-commercialize dosing device
• Manufacturing capacity for coated multiparticulates
• Regional rights outside the United States

Transaction economics should distinguish between technology access and product rights. A formulation licensor may receive an upfront payment, development milestones, royalties, manufacturing revenue, or a combination. The license should define ownership of improvements, regulatory data, manufacturing know-how, field restrictions, geographic rights, and supply obligations.

Key Takeaways

• Tasimelteon has an approved capsule and oral suspension platform.
• The strongest excipient opportunity is a taste-masked, dose-flexible pediatric formulation.
• Dry powder for reconstitution could improve stability, shipping, and international distribution.
• Excipient patents are stronger when tied to measurable performance, not ingredient lists alone.
• A new formulation may require an ANDA, 505(b)(2) application, or supplemental NDA depending on the product and sponsor.
• Capsule generic entry is likely to be technically simpler than suspension entry.
• The commercial value of reformulation depends on caregiver convenience, adherence, reimbursement, and enforceable IP.
• Manufacturing scale-up, flavor consistency, suspension stability, and supplier redundancy are central execution risks.

FAQs

Can tasimelteon be formulated as an orally disintegrating tablet?

Yes. An orally disintegrating tablet is technically feasible, but taste masking, dose uniformity, mechanical strength, moisture sensitivity, and rapid dissolution would need to be demonstrated.

Could a tasimelteon sprinkle formulation replace Hetlioz LQ?

Potentially. A sprinkle product could reduce liquid-handling problems, but the granules would need to remain intact during administration with soft food and provide reliable release after swallowing.

Are flavor patents sufficient to protect a tasimelteon product?

Usually not. Flavor systems may be protected as trade secrets, but durable product exclusivity generally requires composition, particle, process, performance, or packaging claims.

Would a concentrated tasimelteon suspension improve market access?

It could reduce administration volume, but the product would need to maintain acceptable taste, viscosity, sedimentation control, dose uniformity, and in-use stability.

Is a tasimelteon biosimilar possible?

No. Tasimelteon is a small-molecule drug, so the relevant competitive pathway is generic or 505(b)(2) development rather than biosimilar approval.

References

1. U.S. Food and Drug Administration. (2024). Hetlioz and Hetlioz LQ prescribing information.
2. National Library of Medicine. (2024). DailyMed: Hetlioz tasimelteon capsule and Hetlioz LQ tasimelteon suspension.
3. U.S. Food and Drug Administration. (2014). FDA approves Hetlioz to treat Non-24-Hour Sleep-Wake Disorder in totally blind individuals.
4. U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations: Orange Book.
5. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database.